These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

386 related items for PubMed ID: 20817013

  • 1. A clinical study to assess the immunogenicity and safety of a monovalent 2009 influenza A (H1N1) vaccine in an area with low-level epidemics of pandemic influenza.
    Kung HC, Huang KC, Kao TM, Lee YC, Chang FY, Wang NC, Liu YC, Lee WS, Liu HJ, Chen CI, Chen CH, Huang LM, Hsieh SM.
    Vaccine; 2010 Oct 21; 28(45):7337-43. PubMed ID: 20817013
    [Abstract] [Full Text] [Related]

  • 2. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
    Hatz C, von Sonnenburg F, Casula D, Lattanzi M, Leroux-Roels G.
    Vaccine; 2012 May 14; 30(23):3470-7. PubMed ID: 22446638
    [Abstract] [Full Text] [Related]

  • 3. Influenza A (H1N1) 2009 two-dose immunization of US children: an observer-blinded, randomized, placebo-controlled trial.
    Plennevaux E, Blatter M, Cornish MJ, Go K, Kirby D, Wali M, Reeves-Hoché MK, Denis M.
    Vaccine; 2011 Feb 11; 29(8):1569-75. PubMed ID: 21219979
    [Abstract] [Full Text] [Related]

  • 4. Immune response of single dose vaccination against 2009 pandemic influenza A (H1N1) in the Taiwanese elderly.
    Kao TM, Hsieh SM, Kung HC, Lee YC, Huang KC, Huang LM, Chang FY, Wang NC, Liu YC, Lee WS, Liu HE, Chen CI, Chen CH.
    Vaccine; 2010 Aug 31; 28(38):6159-63. PubMed ID: 20659517
    [Abstract] [Full Text] [Related]

  • 5. Response to a monovalent 2009 influenza A (H1N1) vaccine.
    Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, Dawson G, Hu W, Leggio C, Washington D, Basser RL.
    N Engl J Med; 2009 Dec 17; 361(25):2405-13. PubMed ID: 19745216
    [Abstract] [Full Text] [Related]

  • 6. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
    Ehrlich HJ, Müller M, Kollaritsch H, Pinl F, Schmitt B, Zeitlinger M, Loew-Baselli A, Kreil TR, Kistner O, Portsmouth D, Fritsch S, Maritsch F, Aichinger G, Pavlova BG, Barrett PN.
    Vaccine; 2012 Jun 22; 30(30):4543-51. PubMed ID: 22475864
    [Abstract] [Full Text] [Related]

  • 7. Safety and immunogenicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to <18 years of age: a prospective, open-label, multi-center trial.
    Oh CE, Lee J, Kang JH, Hong YJ, Kim YK, Cheong HJ, Ahn YJ, Kim SH, Lee HJ.
    Vaccine; 2010 Aug 16; 28(36):5857-63. PubMed ID: 20600483
    [Abstract] [Full Text] [Related]

  • 8. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.
    Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM.
    Vaccine; 2010 Feb 17; 28(7):1740-5. PubMed ID: 20034605
    [Abstract] [Full Text] [Related]

  • 9. Immunogenicity and safety of influenza A (H1N1) 2009 monovalent inactivated split vaccine in Korea.
    Cheong HJ, Song JY, Heo JY, Noh JY, Choi WS, Park DW, Wie SH, Kim WJ.
    Vaccine; 2011 Jan 10; 29(3):523-7. PubMed ID: 21055502
    [Abstract] [Full Text] [Related]

  • 10. A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations.
    Hatz C, Cramer JP, Vertruyen A, Schwarz TF, von Sonnenburg F, Borkowski A, Lattanzi M, Hilbert AK, Cioppa GD, Leroux-Roels G.
    Vaccine; 2012 Jul 06; 30(32):4820-7. PubMed ID: 22626675
    [Abstract] [Full Text] [Related]

  • 11. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA.
    Pediatrics; 2006 Sep 06; 118(3):e570-8. PubMed ID: 16950948
    [Abstract] [Full Text] [Related]

  • 12. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.
    Fukase H, Furuie H, Yasuda Y, Komatsu R, Matsushita K, Minami T, Suehiro Y, Yotsuyanagi H, Kusadokoro H, Sawata H, Nakura N, Lattanzi M.
    Vaccine; 2012 Jul 13; 30(33):5030-7. PubMed ID: 22472791
    [Abstract] [Full Text] [Related]

  • 13. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM.
    Pediatrics; 2006 Sep 13; 118(3):e579-85. PubMed ID: 16950949
    [Abstract] [Full Text] [Related]

  • 14. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I, Roman F, Forgus S, Maes C, De Boever F, Dramé M, Gillard P, van der Most R, Van Mechelen M, Hanon E, Leroux-Roels G.
    Vaccine; 2010 Jan 08; 28(3):849-57. PubMed ID: 19835828
    [Abstract] [Full Text] [Related]

  • 15. A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems.
    Precioso AR, Miraglia JL, Campos LM, Goulart AC, Timenetsky Mdo C, Cardoso MR, Luna E, Mondini G, Guedes Jda S, Raw I.
    Vaccine; 2011 Nov 08; 29(48):8974-81. PubMed ID: 21945258
    [Abstract] [Full Text] [Related]

  • 16. Immunogenicity and safety of a monovalent vaccine for the 2009 pandemic influenza virus A (H1N1) in children and adolescents.
    Lu CY, Shao PL, Chang LY, Huang YC, Chiu CH, Hsieh YC, Lin TY, Huang LM.
    Vaccine; 2010 Aug 16; 28(36):5864-70. PubMed ID: 20600484
    [Abstract] [Full Text] [Related]

  • 17. Responses after one dose of a monovalent influenza A (H1N1) 2009 inactivated vaccine in Chinese population--a practical observation.
    Sun F, Zhang Y, Tian D, Zheng M, Liu L, Zhang R, Dai Z, Chen J, Li T, Lu H.
    Vaccine; 2011 Sep 02; 29(38):6527-31. PubMed ID: 21767595
    [Abstract] [Full Text] [Related]

  • 18. Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response.
    Taylor DN, Treanor JJ, Sheldon EA, Johnson C, Umlauf S, Song L, Kavita U, Liu G, Tussey L, Ozer K, Hofstaetter T, Shaw A.
    Vaccine; 2012 Aug 24; 30(39):5761-9. PubMed ID: 22796139
    [Abstract] [Full Text] [Related]

  • 19. Poor immune response to a standard single dose non-adjuvanted vaccination against 2009 pandemic H1N1 influenza virus A in the adult and elder hemodialysis patients.
    Chang YT, Guo CY, Tsai MS, Cheng YY, Lin MT, Chen CH, Shen D, Wang JR, Sung JM.
    Vaccine; 2012 Jul 13; 30(33):5009-18. PubMed ID: 22658967
    [Abstract] [Full Text] [Related]

  • 20. Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI).
    Taylor DN, Treanor JJ, Strout C, Johnson C, Fitzgerald T, Kavita U, Ozer K, Tussey L, Shaw A.
    Vaccine; 2011 Jul 12; 29(31):4897-902. PubMed ID: 21596084
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.